Logo image of HOTH

HOTH THERAPEUTICS INC (HOTH) Stock Fundamental Analysis

USA - NASDAQ:HOTH - US44148G2049 - Common Stock

1.27 USD
+0.04 (+3.25%)
Last: 11/10/2025, 8:00:02 PM
1.29 USD
+0.02 (+1.57%)
After Hours: 11/10/2025, 8:00:02 PM
Fundamental Rating

3

Taking everything into account, HOTH scores 3 out of 10 in our fundamental rating. HOTH was compared to 191 industry peers in the Pharmaceuticals industry. While HOTH has a great health rating, there are worries on its profitability. HOTH is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

HOTH had negative earnings in the past year.
In the past year HOTH has reported a negative cash flow from operations.
HOTH had negative earnings in each of the past 5 years.
HOTH had a negative operating cash flow in each of the past 5 years.
HOTH Yearly Net Income VS EBIT VS OCF VS FCFHOTH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M

1.2 Ratios

HOTH's Return On Assets of -100.80% is on the low side compared to the rest of the industry. HOTH is outperformed by 76.96% of its industry peers.
HOTH has a worse Return On Equity (-104.57%) than 61.78% of its industry peers.
Industry RankSector Rank
ROA -100.8%
ROE -104.57%
ROIC N/A
ROA(3y)-118.92%
ROA(5y)-124.88%
ROE(3y)-143.37%
ROE(5y)-145.96%
ROIC(3y)N/A
ROIC(5y)N/A
HOTH Yearly ROA, ROE, ROICHOTH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

1.3 Margins

HOTH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HOTH Yearly Profit, Operating, Gross MarginsHOTH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for HOTH has been increased compared to 1 year ago.
HOTH has more shares outstanding than it did 5 years ago.
HOTH has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
HOTH Yearly Shares OutstandingHOTH Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M
HOTH Yearly Total Debt VS Total AssetsHOTH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

2.2 Solvency

HOTH has an Altman-Z score of 15.51. This indicates that HOTH is financially healthy and has little risk of bankruptcy at the moment.
HOTH has a Altman-Z score of 15.51. This is amongst the best in the industry. HOTH outperforms 89.01% of its industry peers.
There is no outstanding debt for HOTH. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 15.51
ROIC/WACCN/A
WACCN/A
HOTH Yearly LT Debt VS Equity VS FCFHOTH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5M -5M -10M

2.3 Liquidity

A Current Ratio of 27.57 indicates that HOTH has no problem at all paying its short term obligations.
HOTH has a better Current ratio (27.57) than 96.86% of its industry peers.
A Quick Ratio of 27.57 indicates that HOTH has no problem at all paying its short term obligations.
HOTH has a better Quick ratio (27.57) than 96.86% of its industry peers.
Industry RankSector Rank
Current Ratio 27.57
Quick Ratio 27.57
HOTH Yearly Current Assets VS Current LiabilitesHOTH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.95% over the past year.
EPS 1Y (TTM)33.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, HOTH will show a quite strong growth in Earnings Per Share. The EPS will grow by 13.53% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.12%
EPS Next 2Y24.4%
EPS Next 3Y13.53%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HOTH Yearly Revenue VS EstimatesHOTH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2029 2030 2031 2032 100M 200M 300M 400M
HOTH Yearly EPS VS EstimatesHOTH Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HOTH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year HOTH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HOTH Price Earnings VS Forward Price EarningsHOTH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HOTH Per share dataHOTH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1

4.3 Compensation for Growth

A more expensive valuation may be justified as HOTH's earnings are expected to grow with 13.53% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.4%
EPS Next 3Y13.53%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HOTH!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HOTH THERAPEUTICS INC

NASDAQ:HOTH (11/10/2025, 8:00:02 PM)

After market: 1.29 +0.02 (+1.57%)

1.27

+0.04 (+3.25%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-12 2025-08-12/amc
Earnings (Next)11-10 2025-11-10/amc
Inst Owners2%
Inst Owner Change58.66%
Ins Owners4.18%
Ins Owner Change9.41%
Market Cap16.84M
Revenue(TTM)N/A
Net Income(TTM)-10.19M
Analysts82.86
Price Target4.08 (221.26%)
Short Float %3.25%
Short Ratio0.29
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-10.43%
Min EPS beat(2)-19.05%
Max EPS beat(2)-1.81%
EPS beat(4)2
Avg EPS beat(4)1.24%
Min EPS beat(4)-19.05%
Max EPS beat(4)15.21%
EPS beat(8)5
Avg EPS beat(8)12.84%
EPS beat(12)8
Avg EPS beat(12)12.37%
EPS beat(16)10
Avg EPS beat(16)10.44%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-11.11%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)30.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.73
P/tB 1.73
EV/EBITDA N/A
EPS(TTM)-1.07
EYN/A
EPS(NY)-0.6
Fwd EYN/A
FCF(TTM)-0.67
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS0
BVpS0.73
TBVpS0.73
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -100.8%
ROE -104.57%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-118.92%
ROA(5y)-124.88%
ROE(3y)-143.37%
ROE(5y)-145.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 27.57
Quick Ratio 27.57
Altman-Z 15.51
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.95%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%29.17%
EPS Next Y60.12%
EPS Next 2Y24.4%
EPS Next 3Y13.53%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-1.72%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.6%
OCF growth 3YN/A
OCF growth 5YN/A

HOTH THERAPEUTICS INC / HOTH FAQ

What is the fundamental rating for HOTH stock?

ChartMill assigns a fundamental rating of 3 / 10 to HOTH.


Can you provide the valuation status for HOTH THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to HOTH THERAPEUTICS INC (HOTH). This can be considered as Overvalued.


Can you provide the profitability details for HOTH THERAPEUTICS INC?

HOTH THERAPEUTICS INC (HOTH) has a profitability rating of 0 / 10.